Charles River Laboratories International (NYSE: CRL) is expected to report Q2 earnings on Aug. 7. Here's what Wall Street wants to see.

The 10-second takeaway
Comparing the upcoming quarter with the prior-year quarter, average analyst estimates predict Charles River Laboratories International's revenues will decrease -1.0% and EPS will decrease -5.7%.

The average estimate for revenue is $285.3 million. On the bottom line, the average EPS estimate is $0.66.

Revenue details
Last quarter, Charles River Laboratories International booked revenue of $286.0 million. GAAP reported sales were 0.0% higher than the prior-year quarter's $285.8 million.

My

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, non-GAAP EPS came in at $0.70. GAAP EPS of $0.54 for Q1 were 6.9% lower than the prior-year quarter's $0.58 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 36.4%, 40 basis points better than the prior-year quarter. Operating margin was 15.6%, 60 basis points better than the prior-year quarter. Net margin was 9.2%, 180 basis points worse than the prior-year quarter.

Looking ahead
The full year's average estimate for revenue is $1.15 billion. The average EPS estimate is $2.68.

Investor sentiment
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Charles River Laboratories International is hold, with an average price target of $37.72.

Over the decades, small-cap stocks like Charles River Laboratories International have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Get instant access to this free report.